This page contains brief information about brexucabtagene autoleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Brexucabtagene autoleucel is approved to treat adults with:
- Mantle cell lymphoma that has relapsed (come back) or is refractory (does not respond to treatment).
This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that brexucabtagene autoleucel provides a clinical benefit in these patients.
Brexucabtagene autoleucel is only available as part of a special program called Tecartus REMS (Risk Evaluation and Mitigation Strategies).
Brexucabtagene autoleucel is also being studied in the treatment of other types of cancer.
More About Brexucabtagene Autoleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Brexucabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.